Loading
A phase 2 trial of Romidepsin in Cutaneous T-cell lymphoma, run by Celgene, completed.
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) is a phase 2 interventional study registered as NCT00106431 by Celgene, with 102 participants recorded, started 2005-01-01 and reaching its primary completion in 2008-06-01. Interventions recorded: romidepsin (depsipeptide, FK228). Conditions recorded: Cutaneous T-cell Lymphoma.
Linked to the drug Romidepsin because the registry names it among its interventions and Cutaneous T-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
102 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2010-04-23), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| The Percent of Patients (Pts) With Objective Disease Responseprimary | Romidepsin | 96 | 34% | - | - | link |
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) and the tag pipeline.
Shares Romidepsin and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.